515 related articles for article (PubMed ID: 31282759)
21. Drug-resistant cytomegalovirus: clinical implications of specific mutations.
Razonable RR
Curr Opin Organ Transplant; 2018 Aug; 23(4):388-394. PubMed ID: 29794552
[TBL] [Abstract][Full Text] [Related]
22. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis.
Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941
[TBL] [Abstract][Full Text] [Related]
23. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
Razonable RR
Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
[TBL] [Abstract][Full Text] [Related]
24. Prophylactic letermovir decreases cytomegalovirus reactivation after stem cell transplantation: a single-center real-world evidence study.
Serio B; Giudice V; Guariglia R; Fontana R; Pezzullo L; Martorelli MC; Ferrara I; Mettivier L; D'Addona M; Vaccaro E; Langella M; Selleri C
Infez Med; 2021 Mar; 29(1):102-113. PubMed ID: 33664179
[TBL] [Abstract][Full Text] [Related]
25. Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients.
Razonable RR
Clin Microbiol Infect; 2023 Sep; 29(9):1144-1149. PubMed ID: 36963566
[TBL] [Abstract][Full Text] [Related]
26. Characterization of Cytomegalovirus Breakthrough Events in a Phase 2 Prophylaxis Trial of Letermovir (AIC246, MK 8228).
Lischka P; Michel D; Zimmermann H
J Infect Dis; 2016 Jan; 213(1):23-30. PubMed ID: 26113373
[TBL] [Abstract][Full Text] [Related]
27. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir.
Goldner T; Zimmermann H; Lischka P
Antiviral Res; 2015 Apr; 116():48-50. PubMed ID: 25637709
[TBL] [Abstract][Full Text] [Related]
28. Assessment of UL56 Mutations before Letermovir Therapy in Refractory Cytomegalovirus Transplant Recipients.
Santos Bravo M; Tilloy V; Plault N; Palomino SS; Mosquera MM; Navarro Gabriel M; Fernández Avilés F; Suárez Lledó M; Rovira M; Moreno A; Linares L; Bodro M; Hantz S; Alain S; Marcos MÁ
Microbiol Spectr; 2022 Apr; 10(2):e0019122. PubMed ID: 35343771
[No Abstract] [Full Text] [Related]
29. Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.
Hecke SV; Calcoen B; Lagrou K; Maertens J
Future Microbiol; 2019 Feb; 14():175-184. PubMed ID: 30644320
[TBL] [Abstract][Full Text] [Related]
30. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
Kampouri E; Zamora D; Kiem ES; Liu W; Ibrahimi S; Blazevic RL; Lovas EA; Kimball LE; Huang ML; Jerome KR; Ueda Oshima M; Mielcarek M; Zerr DM; Boeckh MJ; Krantz EM; Hill JA
Clin Microbiol Infect; 2023 Nov; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
[TBL] [Abstract][Full Text] [Related]
31. Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Kilgore JT; Becken B; Varga MG; Parikh S; Prasad V; Lugo D; Chang YC
J Pediatric Infect Dis Soc; 2020 Sep; 9(4):486-489. PubMed ID: 31362308
[TBL] [Abstract][Full Text] [Related]
32. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.
Foolad F; Aitken SL; Chemaly RF
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):931-941. PubMed ID: 30004790
[TBL] [Abstract][Full Text] [Related]
33. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
34. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
35. Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis.
Wong DD; van Zuylen WJ; Novos T; Stocker S; Reuter SE; Au J; Foster CSP; Day RO; Horvath AR; Endre Z; Rawlinson WD
Microbiol Spectr; 2022 Jun; 10(3):e0268421. PubMed ID: 35658598
[TBL] [Abstract][Full Text] [Related]
36. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.
El Helou G; Razonable RR
Infect Drug Resist; 2019; 12():1481-1491. PubMed ID: 31239725
[TBL] [Abstract][Full Text] [Related]
37. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis.
Gabanti E; Borsani O; Colombo AA; Zavaglio F; Binaschi L; Caldera D; Sciarra R; Cassinelli G; Alessandrino EP; Bernasconi P; Ferretti VV; Lilleri D; Baldanti F
Transplant Cell Ther; 2022 Apr; 28(4):211.e1-211.e9. PubMed ID: 35042012
[TBL] [Abstract][Full Text] [Related]
38. Maribavir, brincidofovir and letermovir: Efficacy and safety of new antiviral drugs for treating cytomegalovirus infections.
Frange P; Leruez-Ville M
Med Mal Infect; 2018 Dec; 48(8):495-502. PubMed ID: 29650261
[TBL] [Abstract][Full Text] [Related]
39. Successful Treatment of UL97 Mutation Ganciclovir-Resistant Cytomegalovirus Viremia in a Renal Transplant Recipient With Letermovir and Adjunct Hyperimmune Cytomegalovirus Immunoglobulin: A Case Report.
Pearston AP; Ingemi AI; Ripley K; Wilson TJ; Gruber J; McMahon M; Sutton S; Khardori N
Transplant Proc; 2021 May; 53(4):1284-1287. PubMed ID: 33715819
[TBL] [Abstract][Full Text] [Related]
40. Successful ganciclovir treatment of primary cytomegalovirus infection containing the UL97 mutation N510S in an intestinal graft recipient.
Bachmann R; Hamprecht K; Lange J; Ladurner R; Nadalin S; Jahn G; Königsrainer A; Heininger A
Infection; 2013 Aug; 41(4):875-9. PubMed ID: 23546999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]